Sandi Yurichuk

Sandi Yurichuk joined FPG in 2019 and is responsible for transaction execution and support across Ferghana’s biopharma therapeutic and diagnostic practice. Sandi has more than 20 years of executive and entrepreneurial experience in the biopharmaceutical industry, with specialization in oncology, hematology and infectious diseases. Her global business experience encompasses commercial operations, strategic business development, licensing, M&A, franchise development, market access and health policy influence.

Sandi has championed the successful development of strategic clinical and commercialization plans that led to successful product regulatory approvals (FDA, EMA, and international markets), label expansions, life cycle management, licensing deals and corporate M&A transactions.

Sandi began her pharmaceutical career with Eli Lilly’s Hospital Division and later on, was one of the first hires for the Bristol-Myers Oncology Franchise. Sandi spent 16 years with BMS in varying positions of increasing global responsibility with P&L responsibilities exceeding $2B. Following BMS, Sandi worked at Amgen focusing on market expansion of the Neupogen Franchise.

Sandi earned her Bachelor of Science degree from the University of Manitoba with Honors and her Masters of Business Administration from the Canadian Institute of Management. She is the recipient of several outstanding service awards, honors and distinctions including Guest Lecturer at Wharton School of Business.